The oncogenic constitutive activation of the BRAF kinase through mutation accounts for approximately 40–60% of melanoma cases, with 90% of these being V600E mutations (a mutation in codon 600 of exon 15 of the BRAF gene), characterized by the substitution of valine for glutamic acid at codon 600 [4,5]. Here, BRAF is linked to melanoma.